Imunon, Inc. (IMNN)
| Market Cap | 8.22M -34.8% |
| Revenue (ttm) | n/a |
| Net Income | -14.73M |
| EPS | -3.57 |
| Shares Out | 5.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 84,241 |
| Open | 1.490 |
| Previous Close | 1.470 |
| Day's Range | 1.410 - 1.530 |
| 52-Week Range | 1.385 - 5.850 |
| Beta | 1.98 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+1,060.41%) |
| Earnings Date | Aug 11, 2026 |
About IMNN
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for IMNN stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 1,060.41% from the latest price.
News
Imunon enters CRADA with National Cancer Institute for IMNN-001 development
Imunon (IMNN) entered into a Cooperative Research and Development Agreement with the National Cancer Institute, part of the National Institutes of Health. Under the CRADA, Imunon and the NCI’s Cancer…
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J.
IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001
Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones
Imunon Earnings Call Transcript: Q2 2026
Key clinical and operational milestones were achieved, with OVATION 3 phase III enrollment outpacing expectations and strong safety and efficacy data supporting IMNN-001. Financial discipline was maintained, and a $10 million financing extends runway through year-end 2026.
Imunon Earnings release: Q2 2026
Imunon released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Imunon Quarterly report: Q2 2026
Imunon has published its Q2 2026 quarterly earnings report on August 11, 2026.
Imunon reports Q2 EPS (54c), consensus (50c)
“The second quarter brought continued momentum for IMNN-001,” said Stacy Lindborg, President and Chief Executive Officer of IMUNON (IMNN). “Enrollment in our pivotal Phase 3 OVATION 3 study continues ...
Imunon provides update on OVATION 3 trial of IMNN-001
Imunon (IMNN) provided a progress update on its Phase 3 OVATION 3 trial of IMNN-001 in patients with newly diagnosed advanced ovarian cancer. Since initiating the trial, the company has…
IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer
Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION 2 S...
IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development
Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanism
Imunon announces new preliminary data from IMNN-001 trial
Imunon (IMNN) announced new preliminary data from its ongoing Phase 2 minimal residual disease, or MRD, translational clinical trial of IMNN-001, conducted in combination with standard of care neoadju...
IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
Preliminary data reinforces IMNN-001 immunotherapy's potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial
Imunon interim CFO Jeffrey Church to retire, Josh Blacher to succeed
In a regulatory filing, the company stated, “On June 29, 2026, Jeffrey Church informed Imunon (IMNN) of his intent to retire from the position of interim Chief Financial Officer, a…
Imunon Transcript: Life Sciences Virtual Investor Forum
IMNN-001, a first-in-class IL-12 immunotherapy for ovarian cancer, has shown a 14.7-month median overall survival benefit in phase II and is advancing through a phase III trial with strong FDA alignment and a favorable safety profile. The platform holds promise for broader oncology applications.
Imunon Slides: Life Sciences Virtual Investor Forum
Imunon has posted slides in relation to its latest quarterly earnings report, which was published on June 25, 2026.
Imunon announces IDMC recommendation for continuation of OVATION 3 trial
Imunon (IMNN) announced that the independent Data Monitoring Committee, or IDMC, has recommended continuation of the pivotal Phase 3 OVATION 3 clinical trial evaluating IMNN-001 in combination with st...
IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer No...
IMUNON to Present at the Life Sciences Investor Forum on June 25th
LAWRENCEVILLE, N.J., June 22, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lin...
Imunon Transcript: AGM 2026
The meeting highlighted strong clinical progress for IMNN-001, robust financial management, and successful capital raises. All shareholder proposals, including director elections and compensation, were approved by large majorities. No questions were raised by shareholders.
IMUNON Announces Up to $10 Million Cash Financing
Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 million Uniquely structured, flexible financing supports IMUNON's Highly Anticipated Phase 3 OVATI...
Imunon reports Q1 EPS (84c), consensus ($1.28)
“Enrollment in our pivotal Phase 3 OVATION 3 trial continues ahead of plan, reflecting patient interest and strong conviction among principal investigators and the broader medical community in IMNN-00...
Imunon Earnings Call Transcript: Q1 2026
Phase III OVATION 3 trial enrollment is ahead of schedule, with strong clinical data and investigator enthusiasm supporting IMNN-001's potential in ovarian cancer. Financial discipline and creative financing strategies are extending the cash runway, while positive FDA engagement and a robust R&D pipeline position the company for key milestones in 2026 and beyond.
Imunon Earnings release: Q1 2026
Imunon released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Imunon Quarterly report: Q1 2026
Imunon has published its Q1 2026 quarterly earnings report on May 12, 2026.